|drug2510||Placebo 250 cc 24 hours continuous infusion for 15 days Wiki||1.00|
|drug1010||Defibrotide 25 mg/kg 24 hours continuous infusion for 15 days Wiki||1.00|
|D003141||Communicable Diseases NIH||0.07|
There is one clinical trial.
This is a Phase I open-label interventional study which will test the efficacy of ResCure™ in the treatment of patients with COVID-19 infection.
Description: Number of days from COVID-19 diagnosis to recovery via RT-PCRMeasure: The rate of recovery of mild or moderate COVID-19 in patients using ResCure™ Time: 12 Weeks
Description: Reduction and/or progression of symptomatic days, reduction of symptom severityMeasure: Reduction or progression of symptomatic days Time: 12 Weeks
Description: Pulse from baseline to 12 weeksMeasure: Assess the safety of ResCure™ via pulse Time: 12 Weeks
Description: Oxygen saturation from baseline to 12 weeksMeasure: Assess the safety of ResCure™ via oxygen saturation Time: 12 Weeks
Description: EKG from baseline to 12 weeksMeasure: Assess the safety of ResCure™ via EKG Time: 12 Weeks
Description: Assess Adverse Events and Serious Adverse Events due to ResCure™Measure: Assess Tolerability of ResCure™ Time: 12 Weeks
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports